Market news

PLSE’s catheter data and rapid pivotal enrollment showcase that they have a healthy and promising business. I reiterate my “Hold” on PLSE at these levels.

Pulse Biosciences (PLSE) has an average rating of buy and mean price target of $54, according to ana

Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.

HAYWARD, Calif., September 15, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (BTNs). The first patient enrolled in the study completed the final 12-month follow-up visit in August at Sara

Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.

The medical device maker now has a new bull touting its growth potential.

The medical device maker now has a new bull touting its growth potential.

HAYWARD, Calif., August 18, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued

Pulse Biosciences has delivered a very strong share price run, with recent enthusiasm around its atrial fibrillation program now sitting against valuation checks that point to a stock that screens expensive rather than cheap. Over the past 3 years, Pulse Biosciences has returned about 431.5%, which puts a lot of expectation into the current price. Progress in the NANOPULSE-AF pivotal clinical study and advancing regulatory work can support hopes for future commercialisation, while any delay...

Pulse Biosciences (NASDAQ:PLSE) is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Co

Pulse Biosciences (PLSE) is back in focus after reporting wider second quarter losses and announcing a $75 million at the market follow on equity offering, a combination that directly affects existing shareholders. See our latest analysis for Pulse Biosciences. The recent earnings release and the $75 million at the market offering have come after a strong run in Pulse Biosciences' share price, with a 30 day share price return of 55.30% and a 90 day share price return of 73.92%. Over a longer...

Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.

Pulse Biosciences (NASDAQ:PLSE) reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment. Chief Executive Officer and Co-Chairman Paul LaViolette said the company’

HAYWARD, Calif., August 06, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026.

Tipranks Press Release.

HAYWARD, Calif., July 30, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA.

HAYWARD, Calif., July 29, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after commencing the study in April 2026.

Pulse Biosciences (PLSE) just hit a new 5-year high and has strong technical momentum. Shares are up more than 100% over the past 52 weeks. Revenue is projected to surge 652.38% this year and 236.71% next. Analyst sentiment is mixed, with ratings from “Strong Buy” to “Strong Sell,” reflecting its...

HAYWARD, Calif., July 21, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.

HAYWARD, Calif., July 15, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued o